Uploaded August 2025 | Updated September 2026, 2 weeks ago
Tags: Cultivation, Cannabis Breeding, Cannabis Genomics Tools, Trait Selection, Genetic Editing, CRISPR
Moderator: Karl Ravet @advancednutrients
Panelists: Michael Petersen (Wisconsin Crop Innovation Center) , Todd Michael @salkinstitute , Kevin McKernan @medicinal.genomics , and Gabriel Krouk @CNRS
This session delves into the powerful role of genomics in cannabis and modern agriculture. Panelists will introduce key concepts in cannabis genomics, discuss the current landscape of genetic knowledge, and highlight the unexplored potential within the cannabis genome. Attendees will discover how genomics is uncovering genetic diversity and enabling the identification of valuable traits, from pest resistance to enhanced yield. Through tools like marker-assisted selection (MAS),genome-wide association studies (GWAS), and genome editing (CRISPR), participants will learn how to leverage these innovations in breeding programs. Case studies will showcase the practical applications of genomics, demonstrating its transformative impact on developing resilient, high-performing cannabis varieties.
Key Topics Covered:
⦾ Fundamentals of genomics in agriculture and cannabis
⦾ Current understanding and mysteries within the cannabis genome
⦾ Exploring genetic diversity to pinpoint valuable traits
⦾ Advanced breeding tools: MAS, GWAS, and CRISPR
⦾ Real-world case studies in genomics-driven breeding success
Learn More about CannMed: cannmedevents.com
Sign Up for Our Newsletter: share.hsforms.com/1oi57oJDnRN-Uqqc9YPByRA20xr2
The CannMed 25 Innovation & Investment Summit showcased its first international venue, the Wyndham Grand Rio Mar Golf & Beach Resort in Puerto Rico from June 17 - 20, 2025. Since its inception at Harvard Medical School in 2016, CannMed has earned a reputation as the premier destination for cutting-edge research, emerging technologies, and investment opportunities. CannMed 25 continues this tradition with medicinal plant researchers, clinicians and venture capitalists who view this Summit as the industry’s number one showcase for the latest advances in plant-based science, medicine, cultivation, and safety.
Tags: Cultivation, Cannabis Breeding, Cannabis Genomics Tools, Trait Selection, Genetic Editing, CRISPR
Moderator: Karl Ravet @advancednutrients
Panelists: Michael Petersen (Wisconsin Crop Innovation Center) , Todd Michael @salkinstitute , Kevin McKernan @medicinal.genomics , and Gabriel Krouk @CNRS
This session delves into the powerful role of genomics in cannabis and modern agriculture. Panelists will introduce key concepts in cannabis genomics, discuss the current landscape of genetic knowledge, and highlight the unexplored potential within the cannabis genome. Attendees will discover how genomics is uncovering genetic diversity and enabling the identification of valuable traits, from pest resistance to enhanced yield. Through tools like marker-assisted selection (MAS),genome-wide association studies (GWAS), and genome editing (CRISPR), participants will learn how to leverage these innovations in breeding programs. Case studies will showcase the practical applications of genomics, demonstrating its transformative impact on developing resilient, high-performing cannabis varieties.
Key Topics Covered:
⦾ Fundamentals of genomics in agriculture and cannabis
⦾ Current understanding and mysteries within the cannabis genome
⦾ Exploring genetic diversity to pinpoint valuable traits
⦾ Advanced breeding tools: MAS, GWAS, and CRISPR
⦾ Real-world case studies in genomics-driven breeding success
Learn More about CannMed: cannmedevents.com
Sign Up for Our Newsletter: share.hsforms.com/1oi57oJDnRN-Uqqc9YPByRA20xr2
The CannMed 25 Innovation & Investment Summit showcased its first international venue, the Wyndham Grand Rio Mar Golf & Beach Resort in Puerto Rico from June 17 - 20, 2025. Since its inception at Harvard Medical School in 2016, CannMed has earned a reputation as the premier destination for cutting-edge research, emerging technologies, and investment opportunities. CannMed 25 continues this tradition with medicinal plant researchers, clinicians and venture capitalists who view this Summit as the industry’s number one showcase for the latest advances in plant-based science, medicine, cultivation, and safety.

![Why Explore Cannabinoids as an Alternative to Sleep Medicine for Children with ASD? - Mohsin Maqbool
Why Explore Cannabinoids as an Alternative to Sleep Medicine for Children with Autism Spectrum Disorder (ASD)?
Dr. Mohsin Maqbool is a pediatric neurologist and sleep specialist based in Dallas–Fort Worth, Texas. His work focuses on the intersection of neurodevelopment, sleep, and cannabinoid therapeutics in autism spectrum disorder. He is particularly interested in how cannabinoid formulations may influence sleep regulation, behavior, and quality of life in children with autism.
At CannMed 26, Mohsin will present “Autism, Sleep, and Medicinal Cannabis: Evaluating 18-Month Efficacy and Safety Outcomes”
During our conversation, we discuss:
- The gaps in current sleep medicine for children with Autism Spectrum Disorder
- Results from Mohsin’s 18-month longitudinal study including improvements to total sleep time, sleep onset and maintenance, and overall quality of sleep
- The method of finding the effective dose for each patient
- Cannabinoids’ effect on the duration of REM sleep and what the daytime implications are
- Thinking of cannabis as a tool to supplement conventional ASD medications and not a replacement
- Future research directions - using wearables and EEG to investigate how cannabinoids affect sleep architecture and brain physiology, as well as using biomarkers to see whether patients are a good candidate for cannabinoid therapies
Thanks to This Episode’s Sponsor: The Society of Cannabis Clinicians
The Society of Cannabis Clinicians is a nonprofit professional association of physicians and other healthcare providers. It provides continuing education—for clinicians, patients, and all concerned about the medical use of cannabis and best practices in clinical care. SCC physicians have been monitoring cannabis use by patients for 20 years and have compiled a wealth of clinical evidence and treatment strategies that will be validated by clinical trials in the years ahead.
To learn more about SCC and to join visit cannabisclinicians.org.
Additional Resources
- Effects of Medical Cannabis Treatment for Autistic Children on Family Accommodation: An Open-Label Mixed-Methods Study - https://pmc.ncbi.nlm.nih.gov/articles/PMC12563248/
- [Book] Cannabis Is Medicine: How Medical Cannabis and CBD Are Healing Everything from Anxiety to Chronic Pain by Dr. Bonni Goldstein - https://www.amazon.com/Cannabis-Medicine-Medical-Healing-Everything/dp/031650078X
- Register for CannMed 26 - https://cannmedevents.com/package-options/
- Meet the CannMed 26 Speakers - https://cannmedevents.com/speakers/
- Review the Podcast - https://podcasts.apple.com/us/podcast/cannmed-coffee-talk/id1504218804
- CannMed Archive - https://cannmedevents.com/cannmed-video-archives/ Why Explore Cannabinoids as an Alternative to Sleep Medicine for Children with ASD? - Mohsin Maqbool](https://i.ytimg.com/vi/icACT6YW4Zg/mqdefault.jpg)
![Why is opioid respiratory induced depression a critical target for overdose prevention? - Beth Wiese
Dr. Beth Weise is the Research and Overdose Prevention Coordinator for The Sidewalk Project, a non-profit organization that aids unhoused, drug-using, survivor & sex worker populations by providing direct services including crisis response, system advocacy, wound care, job placement, medication-assisted treatment (MAT), and creative community resources for mental health. Her work aims to influence future drug policy with novel evidence-based research that also advocates and empowers people who use drugs to feel safe and prevent fatal overdose
At CannMed 26, Beth will present Cannabidiol to Mitigate Opioid Induced Respiratory Depression. During our conversation, we discuss:
- What causes Opioid Induced Respiratory Depression and how cannabinoids play a role
- How CBD can be used in combination with Naloxone to reduce withdrawal-related side effects
- How Beth’s research can be applied in real-world scenarios
Thanks to This Episode’s Sponsor: Humanity Heroes
Humanity Heroes provides compassionate support to the unhoused community by delivering essential supplies and resources directly to those in need. Humanity Heroes partners with other nonprofits by empowering them to extend their reach and impact within their own communities. Together, they strive to create a world where every person has access to the resources and support they need to thrive.
Learn more at JoinHumanityHeroes.org
Additional Resources:
- THRRIV.org
- [Webinar] Bridging the Gap: Tech-Supported Peer Connections to Reduce - - Overdose Fatalities - https://www.youtube.com/watch?v=tralDTJlhqs
Register for CannMed 26 - cannmedevents.com Why is opioid respiratory induced depression a critical target for overdose prevention? - Beth Wiese](https://i.ytimg.com/vi/igk2lq5ZNxA/mqdefault.jpg)







